Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Helge Müller

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Statistics in Medicine|April 30, 2004
Construction of group sequential designs in clinical trials on the basis of detectable treatment differencesHelmut Schäfer, Hans-Helge Müller
Statistics in Medicine|August 3, 2004
A general statistical principle for changing a design any time during the course of a trialHans-Helge Müller, Helmut Schäfer
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
An overview of statistical approaches for adaptive designs and design modificationsHelmut Schäfer, Nina Timmesfeld, Hans-Helge Müller
European Journal of Dermatology : EJD|March 23, 2026
Skin physiology during daylight photodynamic therapy with additional fractional laser therapyNatalya Ilina, Hans-Helge Müller, Harald Löffler
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|July 10, 2003
Prevalence of potential noninvasive arrhythmia risk predictors in healthy, middle-aged personsWolfram Grimm, Julia Liedtke, Hans-Helge Müller
Biostatistics (Oxford, England)|December 17, 2008
Optimal multistage designs--a general framework for efficient genome-wide association studiesRoman Pahl, Helmut Schäfer, Hans-Helge Müller
Statistics in Medicine|November 3, 2006
Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rateNina Timmesfeld, Helmut Schäfer, Hans-Helge Müller
Genetic Epidemiology|June 6, 2007
Including sampling and phenotyping costs into the optimization of two stage designs for genomewide association studiesHans-Helge Müller, Roman Pahl, Helmut Schäfer
Anticancer Research|October 26, 2022
Prognostic Significance of the Nodal Ratio and Number of Positive Nodes in Patients With Squamous Cell Carcinomas of the Head and NeckIsabell Reuter, Hans-Helge Müller, Susanne Wiegand
Plos One|July 25, 2022
Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction-Validation and refinement of a multivariable prediction modelChristoph Paul, Hans-Helge Müller, Thomas Raber, et al.
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Statistics in Medicine|April 30, 2004
Construction of group sequential designs in clinical trials on the basis of detectable treatment differencesHelmut Schäfer, Hans-Helge Müller
Statistics in Medicine|August 3, 2004
A general statistical principle for changing a design any time during the course of a trialHans-Helge Müller, Helmut Schäfer
Biometrical Journal. Biometrische Zeitschrift|September 16, 2006
An overview of statistical approaches for adaptive designs and design modificationsHelmut Schäfer, Nina Timmesfeld, Hans-Helge Müller
European Journal of Dermatology : EJD|March 23, 2026
Skin physiology during daylight photodynamic therapy with additional fractional laser therapyNatalya Ilina, Hans-Helge Müller, Harald Löffler
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|July 10, 2003
Prevalence of potential noninvasive arrhythmia risk predictors in healthy, middle-aged personsWolfram Grimm, Julia Liedtke, Hans-Helge Müller
Biostatistics (Oxford, England)|December 17, 2008
Optimal multistage designs--a general framework for efficient genome-wide association studiesRoman Pahl, Helmut Schäfer, Hans-Helge Müller
Statistics in Medicine|November 3, 2006
Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rateNina Timmesfeld, Helmut Schäfer, Hans-Helge Müller
Genetic Epidemiology|June 6, 2007
Including sampling and phenotyping costs into the optimization of two stage designs for genomewide association studiesHans-Helge Müller, Roman Pahl, Helmut Schäfer
Anticancer Research|October 26, 2022
Prognostic Significance of the Nodal Ratio and Number of Positive Nodes in Patients With Squamous Cell Carcinomas of the Head and NeckIsabell Reuter, Hans-Helge Müller, Susanne Wiegand
Plos One|July 25, 2022
Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction-Validation and refinement of a multivariable prediction modelChristoph Paul, Hans-Helge Müller, Thomas Raber, et al.
Pageof 8